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Introduction: Peroxiredoxin-1 (PRDX1) is a multifunctional protein, acting as a hydrogen peroxide (H2O2) scavenger,
molecular chaperone and immune modulator. Although differential PRDX1 expression has been described in many
tumors, the potential role of PRDX1 in breast cancer remains highly ambiguous. Using a comprehensive antibody-based
proteomics approach, we interrogated PRDX1 protein as a putative biomarker in estrogen receptor (ER)-positive breast
cancer.
Methods: An anti-PRDX1 antibody was validated in breast cancer cell lines using immunoblotting, immunohistochemistry
and reverse phase protein array (RPPA) technology. PRDX1 protein expression was evaluated in two independent breast
cancer cohorts, represented on a screening RPPA (n = 712) and a validation tissue microarray (n = 498). In vitro assays
were performed exploring the functional contribution of PRDX1, with oxidative stress conditions mimicked via
treatment with H2O2, peroxynitrite, or adenanthin, a PRDX1/2 inhibitor.
Results: In ER-positive cases, high PRDX1 protein expression is a biomarker of improved prognosis across both cohorts.
In the validation cohort, high PRDX1 expression was an independent predictor of improved relapse-free survival (hazard
ratio (HR) = 0.62, 95% confidence interval (CI) = 0.40 to 0.96, P = 0.032), breast cancer-specific survival (HR = 0.44,
95% CI = 0.24 to 0.79, P = 0.006) and overall survival (HR = 0.61, 95% CI = 0.44 to 0.85, P = 0.004). RPPA screening of
cancer signaling proteins showed that ERα protein was upregulated in PRDX1 high tumors. Exogenous H2O2
treatment decreased ERα protein levels in ER-positive cells. PRDX1 knockdown further sensitized cells to H2O2- and
peroxynitrite-mediated effects, whilst PRDX1 overexpression protected against this response. Inhibition of PRDX1/2
antioxidant activity with adenanthin dramatically reduced ERα levels in breast cancer cells.
Conclusions: PRDX1 is shown to be an independent predictor of improved outcomes in ER-positive breast cancer.
Through its antioxidant function, PRDX1 may prevent oxidative stress-mediated ERα loss, thereby potentially
contributing to maintenance of an ER-positive phenotype in mammary tumors. These results for the first time
imply a close connection between biological activity of PRDX1 and regulation of estrogen-mediated signaling in
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Molecular classification of breast cancer cases using
biomarkers in tumor cells provides an opportunity for
the implementation of effective targeted treatment
modalities, such as the expression of estrogen receptor
(ER) and responses to endocrine therapy. However,
despite the benefits gained by endocrine treatment, the
long-term effectiveness of such targeted approaches is
still unsatisfactory. Identifying novel biomarkers predictive
of clinical outcome is desirable in order to guide clinicians
in selecting new treatment options and monitoring the
treatment response of patients, as well as potentially
identifying new mechanisms that could lead to combina-
tions with hormonal therapy.
Peroxiredoxins are a ubiquitous family of antioxidant
enzymes, known to catalyze peroxide reduction to balance
cellular hydrogen peroxide (H2O2) levels, which is essential
for cell signaling and metabolism [1,2]. Of particular inter-
est is the mammalian isoform, peroxiredoxin 1 (PRDX1),
which is a multifunctional protein originally identified as an
intracellular scavenger of H2O2 [3]. It has been also shown
to act as a molecular chaperone with the ability to modu-
late the actions of numerous molecules [4-8], a regulator of
transcription [9], or as an immunomodulator [10]. There
are multiple reports of differential PRDX1 expression in
human malignancies (reviewed in [11]). However, the diver-
sity of PRDX1 functions makes the prediction of its role in
human tumors difficult. Further validation is necessary to
address the importance of PRDX1 protein expression in
each cancer type.
The specific role for PRDX1 in breast cancer is contro-
versial. In an earlier study, PRDX1 protein was found to
be overexpressed in malignant versus normal tissues in
21 of 24 patients, but no significant relationship was found
between PRDX1 overexpression and common clinicopath-
ological parameters of breast cancer [12]. In a cohort of
475 patients, it was reported that PRDX1 protein expres-
sion in breast cancer was not significantly associated with
any clinicopathological parameter [13]. However, other
studies have shown that overexpression of PRDX1 mRNA
in human breast carcinoma is associated with higher tumor
grade [14], and high expression of cytoplasmic PRDX1
protein correlated with increased risk of local recurrence
after radiotherapy [15].
Conversely, several lines of evidence suggest that
PRDX1 may act as a tumor suppressor in breast cancer.
Prdx1-deficient mice suffer from shortened survival due
to development of hemolytic anemia and multiple tumors,
including mammary carcinomas [16]. PRDX1, acting as a
chaperone, interacts with the c-Myc oncogene and sup-
presses its transcriptional activity [17]. Another proposed
function for PRDX1 in breast cancer is as a sensor in
H2O2-mediated stress-induced senescence [5]. Further-
more, Cao et al. have shown that PRDX1 protects thetumor suppressive function of PTEN phosphatase, likely
due to the presence of a reactive oxygen species (ROS)
sensitive cysteine in the catalytic domain, and reduces
predisposition of genetically modified mice to develop
Ras-induced mammary tumors [6]. Accordingly, a recent
study suggests that high PRDX1 expression appears to be
associated with less aggressive breast cancers [18].
Importantly, a number of the above biomarker studies
suffer from shortcomings such as lack of appropriate
antibody validation, small cohort size and/or the absence
of a molecular explanation supporting the clinical data.
Thus, there is an ongoing need for properly designed
studies on the role of PRDX1 in breast cancer that follow
the REMARK guidelines for prognostic biomarkers [19].
This is especially relevant in light of PRDX1 being con-
sidered a therapeutic target in other cancer types, as
well as the recent development of adenanthin as a
chemical inhibitor of PRDX1/2 [20].
Herein, we demonstrate a robust approach for interro-
gating the role of PRDX1 as a putative protein biomarker
in breast cancer. We identify PRDX1 expression levels as
an independent marker of favorable outcome in ER-
positive tumors and elucidate a unique role for PRDX1 in




ZR-75-1, T47D, MCF7 and SKBR3 cell lines were pur-
chased from the European Collection of Cell Cultures
(Wiltshire, UK). All cell lines were maintained through
continuous passaging, and were confirmed to be free of
contamination by Mycoplasma spp. Cells were main-
tained in DMEM (ZR-75-1 cell line) or RPMI-1640
(other cell lines) media (Sigma-Aldrich, St. Louis, MO,
USA), with 10% FBS (Sigma-Aldrich), 100 U/mL penicil-
lin, 100 μg/mL streptomycin (Gibco, Rockville, MD, USA)
and 1.46 mg/mL L-glutamine (Gibco). Additionally, the
growth medium for ZR-75-1 was supplemented with 1
nM β-estradiol (Sigma-Aldrich), and did not contain so-
dium pyruvate, which mediates elimination of H2O2 from
the culture medium [21]. Tissue culture experimental
techniques are further described in the Supplementary
Methods (Additional file 1).
Chemical reagents
Adenanthin has been generated as previously described
[20]. H2O2 and peroxynitrite were obtained from Sigma-
Aldrich and Millipore (Billerica, MA, USA), respectively.
Antibody validation and immunohistochemistry
Antibody generation against PRDX1 was as described
previously [22]. The Human Protein Atlas (HPA) Consor-
tium carried out the initial quality control of the polyclonal
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testing on a variety of tissues (48 normal tissues and 16
cancer tissues) [23]. Immunoblotting and immunohisto-
chemistry procedures are described in Supplementary
Methods (Additional file 1).
Patient cohorts
Clinical materials originating from three independent co-
horts of breast cancer patients were utilized in this study.
Demographic and clinical characteristics for all cohorts
are presented in this study are described in Supplementary
Table S1 (Additional file 2).
Cohort 1 was represented on a reverse phase protein
array (RPPA) containing protein extracts from 58 breast
cancer cell lines and 998 human breast tumors, with
available clinicopathological data for 712 cases. The clin-
ical samples were collected at M. D. Anderson Cancer
Center (MDACC) Houston, TX, USA, Hospital Clinico
Universitario de Valencia, Spain, University of British
Columbia, Vancouver, BC, Canada and Baylor College of
Medicine, Houston, TX, USA [24]. Complete clinical infor-
mation was available for 574 patients. All tumors in this
training set were collected by excision during their primary
surgery, followed by freezing of the tissue. Tumor content
was verified by histopathology. All tissues were collected
under Institutional Review Board (IRB)-approved labora-
tory protocols, awarded by the M. D. Anderson Cancer
Center IRB, University of British Columbia IRB, and the
Hospital Clinico Universitario de Valencia IRB. Patients
consented to bank their specimens. As this was a retro-
spective study, each IRB provided a waiver of informed
consent.
Cohort 2 consisted of a tissue microarray (TMA) with
498 consecutive invasive breast cancer cases (442 in final
analysis) diagnosed at the Department of Pathology,
Malmö University Hospital, between 1987 and 1992 [25].
The median age at diagnosis was 65 years (range, 27 to
96) and the median follow-up time was 11 years (range, 0
to 17). Two hundred and sixty-three patients were dead at
the last follow-up (December 2004), 90 of whom were
considered to be as a direct result of breast cancer (breast
cancer-specific death). Complete endocrine treatment data
were available for 379 patients, 160 of whom received ad-
juvant tamoxifen. Information on adjuvant chemotherapy
was available for 382 patients, of whom 23 patients re-
ceived treatment. The study has been approved by the
Ethics Committee at Lund University. Informed consent
was obtained for all included patients and opting out
was an option.
Cohort 3 was represented on a RPPA consisting of 410
primary breast tumors collected by The Cancer Genome
Atlas (TCGA) Consortium. These frozen primary tumor
specimens collected from newly diagnosed patients
with invasive breast adenocarcinoma undergoing surgicalresection and who had received no prior treatment for
their disease (chemotherapy or radiotherapy). Owing to
the short median overall follow-up (20 months) and the
small number of overall survival events (44 out of 410),
survival analysis was not carried out on this cohort. This
cohort was used solely to correlate quantitative levels of
PRDX1 protein expression with expression of 180+ other
proteins assessed on the same array. The TCGA project
collects high-quality breast tumor samples and makes
available the clinical information, molecular/genomic pro-
filing data, and histopathology slide images on the TCGA
data portal [26]. The TCGA data is organized into two
categories: one that is openly accessible to the public
and one that has controlled access, available only to
qualified researchers obligated to secure the data. The
open access data set contains only information that is
not individually unique and does not pose a risk of patient
re-identification. All the data used within this manuscript
was obtained from the open access data set and has
passed the criteria for unrestricted publication with the
following statement ‘No restrictions; all data available
without limitations’ listed at the publication guidelines
section of the TCGA data portal [26].
Reverse phase protein array analysis
Protein was extracted from tumor tissue and cell lines
and probed for protein expression by reverse phase
protein array (RPPA) analysis as previously described
[24,27-30]. RPPA analysis was completed independently
for cohorts 1 and 3. The technique is further described in
the Supplementary Methods (Additional file 1).
Evaluation of immunohistochemical staining
Slides were scanned at 20X magnification using a Scan-
Scope XT slide scanner (Aperio Technologies, Vista, CA,
USA). The Spectrum Analysis algorithm package, Image-
Scope analysis software and Color Deconvolution algo-
rithm (version 9; Aperio Technologies.) were applied to
quantify immunohistochemical (IHC) staining. These al-
gorithms were used to calculate the average positive
intensity (API), as well as the area of positive staining,
and the percentage of weak (1+), medium (2+), and
strong (3+) positive staining. The final API was sub-
tracted from 255, as these intensity ranges on an 8-bit
scale of 0 to 255 (black to white, respectively). The
maximum value from both cores for each patient was
used for statistical analysis.
Statistical analysis
All statistical analysis was carried out with PASW Statistics
version 20 and R Project for Statistical Computing. Spear-
man’s rho test was used to compare protein expression
across the recombinant cell line series in the immuno-
blotting and RPPA setting. In cohorts 1 and 2, the
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into high and low PRDX1 expression. Pearson’s χ2 test
and Fisher’s exact test were used to evaluate associations
between protein expression and clinicopathological vari-
ables. Kaplan-Meier, univariate and multivariate Cox re-
gression analyses were used to illustrate differences
between recurrence-free survival (RFS), breast cancer-
specific survival (BCCS), and overall survival (OS) accord-
ing to PRDX1 expression. In cohort 3, the Pearson’s
correlation test was used to determine the correlation
between PRDX1 and expression of other proteins, and
the two-sided t test was used to identify proteins co-
regulated between the lower and upper quartile of PRDX1
protein expression cases. In all experiments, a two-tailed
test value of less than 0.05 was considered significant.
Results
Validation of PRDX1 antibody across different protein
quantification platforms
In light of conflicting results regarding the prognostic
relevance of PRDX1 expression in breast cancer, a funda-
mental step for our study was comprehensive validation of
the anti-PRDX1 antibody. Antibody specificity was con-
firmed in several breast cancer cell lines (T47D, ZR-75-1
and SKBR3), whereby PRDX1 expression was modified
using short hairpin loop RNA (shRNA)-mediated gene
knockdown and overexpression of cDNA encoding
V5-tagged PRDX1, before antibody validation by im-
munoblotting (Figure 1A and C; complete gel displayed
in Figure S1A in Additional file 3), RPPA analysis
(Figure 1B) and IHC (Figure 1D and E). IHC performed
on formalin-fixed paraffin-embedded (FFPE) SKBR3 cells
revealed a decrease in staining intensity in cells expressing
either of two shRNA molecules against PRDX1 (Figure 1D,
lower panel) compared to non-targeting or parental cell
controls. A significant decrease was seen in percentage
3,3-diaminobenzidine (DAB) positivity of these knock-
down cells (Figure 1E). This observation confirmed the
specificity of the antibody in the IHC setting prior to
staining of clinical specimens. Figure 1F shows representa-
tive examples of different intensities of DAB staining, that
is, expression of PRDX1 protein on TMA cores. PRDX1
protein expression was found to be predominantly cyto-
plasmic throughout the cores (Figure 1G). An automated
algorithm was used to develop a quantitative scoring
model of PRDX1 protein expression, with the respective
mark-up image shown. To rule out the possibility of the
antibody binding to PRDX2, a protein with high homology
for PRDX1, cell lines overexpressing a pLenti6-PRDX2-V5
plasmid were generated. Modulation of PRDX1 expression
levels did not affect PRDX2 protein expression, and vice
versa (Figure S1D in Additional file 3). An additional
PRDX1-targeting antibody was tested [18]; however, this
antibody did not satisfactorily detect differential proteinexpression compared to mRNA expression measured
in the shRNA-expressing cell lines (Figure S1B-C in
Additional file 3). These extensive validation steps allow us
a high level of certainty that the antibody used is specific to
PRDX1 in all techniques used throughout the study.
Identification of PRDX1 protein as a biomarker of good
prognosis in ER-positive breast tumors
RPPA technology is a particularly useful tool to aid in
the identification and validation of protein and phospho-
protein biomarkers using limited amounts of protein from
clinical samples. PRDX1 protein expression was assessed
on a RPPA cohort with clinical data available for 712 pri-
mary human breast tumors. Protein expression data was
dichotomized based on the median PRDX1 expression
values. High PRDX1 expression was associated with low
tumor grade (P <0.001), older age at diagnosis (P <0.001)
and human epidermal growth factor receptor 2 (Her2)
negativity (P = 0.001), while it displayed a borderline
association with positive ER status (P = 0.05) (Table S2
in Additional file 2).
Kaplan-Meier analysis demonstrated that increased
levels of PRDX1 protein expression were associated
with improved RFS (P = 0.004), OS (P = 0.036) and BCSS
(P = 0.005). Interestingly, when various subcohorts were
analyzed, high PRDX1 was associated with improved RFS
(P = 0.010) and BCSS (P = 0.013) only in the subgroup of
ER-positive tumors (Figure 2). Univariate Cox regression
analysis demonstrated that, in these ER-positive cases,
PRDX1 was associated with improved RFS (hazard ratio
(HR) = 0.62, 95% confidence interval (CI) = 0.43 to 0.90,
P = 0.011) and BCSS (HR = 0.59, 95% CI = 0.39 to 0.90,
P = 0.014) (Table 1). When evaluated by a multivariate
Cox proportional hazards model, PRDX1, as assessed by
RPPA, was not an independent predictor of RFS or OS
(Table 1). However, high PRDX1 protein levels trended
toward a significant association with improved BCSS
(HR = 0.56, 95% CI = 0.31 to 1.01, P = 0.055).
PRDX1 protein levels, as assessed by IHC, is an independent
predictor of prognosis in ER-positive breast tumors
Although RPPA technology is an ideal platform for initial
biomarker discovery, it was necessary to validate these
findings in an independent cohort using a more clinically
applicable platform, namely IHC (cohort 2). Due to core
loss during sectioning, tumors from 442 (88.8%) patients
were suitable for analysis. IHC staining was scored on a
continuous scale based on staining intensity (Figure 1F),
and the median expression level was used to stratify the
cohort into high and low PRDX1 protein staining. On
the basis of this classification, any possible associations
between protein expression and a variety of well-defined
clinicopathological variables in the TMA cohort were
investigated (Table S3 in Additional file 2). PRDX1
Figure 1 Validation of the PRDX1 antibody specificity using immunoblotting, RPPA and IHC platforms. (A) Immunoblotting shows a
discrete signal, the intensity of which correlates with PRDX1 knockdown/overexpression across recombinant ZR-75-1 cell lines (V5-tagged PRDX1
protein runs at 25 kDa, with native protein at 22 kDa). (B) Correlation between Western blotting densitometry and RPPA log2 expression values
from recombinant ZR-75-1 cell lines protein lysates. (C) Immunoblotting, (D) cell pellet arrays (upper panels: DAB and hematoxylin staining; lower
panel: DAB staining only) and (E) automated analysis scoring from recombinant SKBR3 breast cancer cell lines (automated scoring includes data
from cells stained with PRDX1 antibody or PBS-T only control). (F) Representation of tissue cores and associated mark-up images after automated
analysis (x40 magnification). (G) Example of PRDX1 cytoplasmic staining. (ns: non-significant; **P <0.01; ***P <0.001). IHC, immunohistochemistry;
PBS-T, phosphate-buffered saline with 0.1% Tween-20; PRDX1, peroxiredoxin 1; RPPA, reverse phase protein arrays.
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(P = 0.011), low tumor grade (P = 0.002), negative Ki67
status (P = 0.004) and lobular subtype (P = 0.003), whilst
there was a borderline significant correlation with positive
ER status (P = 0.05).
The relationship between differential expression of
PRDX1 and patient survival was subsequently exam-
ined. In the overall cohort, increased levels of PRDX1
protein trended toward an improved RFS (P = 0.061),
OS (P = 0.100) and BCSS (P = 0.068), but these values
were not significant. The positive correlation between
high PRDX1 expression and favorable prognosis was again
limited to the ER-positive subgroup of cases. Kaplan-Meier
analysis demonstrated that, in the ER-positive subgroup,
increased levels of PRDX1 protein were associated with
an improved RFS (P = 0.011), OS (P = 0.010) and BCSS(P = 0.002) (Figure 3). To compare the prognostic impact
of PRDX1 with established factors, Cox regression analysis
was performed (Table 2). Univariate Cox regression ana-
lysis confirmed that, in ER-positive tumors, high PRDX1
expression associated with improved RFS (HR = 0.60,
95% CI = 0.40 to 0.89, P = 0.012), BCSS (HR = 0.69, 95%
CI = 0.52 to 0.92, P = 0.010) and OS (HR = 0.44, 95%
CI = 0.24 to 0.75, P = 0.003). Importantly, multivariate
analysis within the ER-positive subset showed that
PRDX1 was a significant independent predictor of im-
proved RFS (HR = 0.62, 95% CI = 0.40 to 0.96, P = 0.032),
BCSS (HR = 0.44, 95% CI = 0.24 to 0.79, P = 0.006) and OS
(HR = 0.61, 95% CI = 0.44 to 0.85, P = 0.004), when ad-
justed for well-established variables such as tumor size,
grade, age, nodal, progesterone receptor (PR), Her2 and
Ki67 status (Table 2).
Figure 2 Prognostic value of PRDX1 protein in ER-positive breast tumors on an RPPA cohort (cohort 1). Kaplan-Meier analysis showing
associations between (A) RFS, (B) BCSS and (C) OS with high/low PRDX1 expression stratified by the median. The overall and ER + cohorts are
shown. Significant log-rank P values are in italic (P <0.05). BCSS, breast cancer-specific survival; ER, estrogen receptor; PRDX1, peroxiredoxin 1; OS,
overall survival; RFS, recurrence-free survival; RPPA, reverse phase protein arrays.
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cancer-related signaling proteins in clinical breast
cancer samples
RPPA technology can be used to explore cellular signaling
pathways activated during cancer progression, such as
proteins involved in cellular functions such as growth,
proliferation and apoptosis [27]. Utilizing an independentcohort of 410 patients (cohort 3), quantitative protein and
phosphoprotein expression levels (165 proteins assessed)
were screened to identify alterations in response to dif-
ferential PRDX1 protein expression. This cohort was
stratified into ER-positive and ER-negative cohorts based
on the quantitative level of ERα protein expression
(Figure 4A). This analysis showed a large number of the
Table 1 Cox univariate and multivariate analysis of RFS, BCSS and OS in cohort 1 (RPPA), and also stratified into the
ER-positive cohort
RFS BCSS OS
HR (95% CI) P HR (95% CI) P HR (95% CI) P
All patients (n = 712)
PRDX1 protein Univariate Univariate Univariate
Low 1 1 1
High# 0.67 (0.52 - 0.88) 0.004 0.65 (0.48 - 0.88) 0.005 0.76 (0.59 - 0.98) 0.036
PRDX1 protein Multivariate* Multivariate* Multivariate*
Low 1 1 1
High# 0.94 (0.65 - 1.35) 0.720 0.84 (0.55 - 1.28) 0.405 0.93 (0.66 - 1.31) 0.668
ER + patients (n = 429)
PRDX1 protein Univariate Univariate Univariate
Low 1 1 1
High# 0.62 (0.43 - 0.90) 0.011 0.59 (0.39 – 0.90) 0.014 0.79 (0.57 - 1.11) 0.171
PRDX1 protein Multivariate* Multivariate* Multivariate*
Low 1 1 1
High# 0.65 (0.37 - 1.13) 0.129 0.56 (0.31 - 1.01) 0.055 0.78 (0.50 - 1.23) 0.295
*Multivariate analysis included adjustment for tumor size, grade, age, nodal, ER, PR and Her2 status. Tumor size and age are both continuous variables. PRDX1
protein expression levels are stratified by the median. #PRDX1 protein expression levels are stratified by the median protein expression value. BCSS, breast
cancer-specific survival; CI, confidence interval; ER, estrogen receptor; Her2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival; PR,
progesterone receptor; PRDX1, peroxiredoxin 1; RFS, recurrence-free survival; RPPA, reverse phase protein arrays.
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pression in the ER-positive cohort (Table S4 in Additional
file 2). Thus, a more stringent approach was necessary
to refine the proteins altered in response to differential
PRDX1 expression levels, whereby proteins altered be-
tween the highest quartile (75th percentile and above)
versus the lowest quartile (up to 25th percentile) of
PRDX1 expression were selected (Figure 4B). A statistically
significant positive correlation was seen between PRDX1
protein and ERα (fold change (FC) = 1.54, P = 0.017). Other
proteins that were altered include Claudin-7 (FC = 1.60,
P <0.001), HSP70 (FC = 0.61, P <0.001), Collagen VI
(FC = 0.61, P = 0.009) and pThr202/pTyr204-MAPK
(FC = 0.65, P = 0.008) (Table 3) (represented graphically
in Figure 4C). Interestingly, several of the proteins which
correlated with PRDX1 expression are known to be regu-
lated by oxidative stress and/or play a role in signaling in
the context of ER-positive breast cancer.
PRDX1 protects against oxidative stress-induced
ERα suppression
Since the hypoxic environment of tumors is likely to
contain high levels of ROS [31], induction of oxidative
stress in cell lines may be a close mimic of intra-tumoral
conditions. In addition, oxidative stress is a very well-
known modulator of several oncogenic signaling path-
ways, including the Akt-mediated pathway, where effects
of PRDX1 have been already described in mouse mam-
mary tissue [6]. Therefore, we examined whether breastcancer cell lines exposed to oxidative stress had altered
levels of these estrogen and breast cancer signaling pro-
teins, and if modulation of PRDX1 expression could alter
any oxidative stress-induced signaling changes. Increased
oxidative stress was accomplished via treatment with ex-
ogenous H2O2 or peroxynitrite. The ER-positive ductal
carcinoma cell line, ZR-75-1, was primarily utilized, being
a standard model of ER-positive and estrogen-dependent
tumors, with low-level oncogenic signaling [32,33]. In
the previous RPPA screen, we observed that ERα and
pThr202/pTyr204-MAPK were associated with PRDX1
protein expression in ER-positive tumors (cohort 3).
Thus, we set about validating these findings in our model
cell line. We observed that H2O2 treatment resulted in
decreased ERα protein expression in parental ZR-75-1
cells with suppression of the ER activity surrogate, PR, as
well as enhanced phosphorylation of serine 473 on Akt,
another oncogenic signaling molecule (Figure S2A in
Additional file 4).
Subsequent studies demonstrated that oxidative stress-
mediated suppression of ERα can be regulated by inducing
changes in PRDX1 protein expression. In two independ-
ently transduced ZR-75-1 cell lines stably expressing
different PRDX1-targeting shRNAs, PRDX1 knockdown-
enhanced H2O2-mediated suppression of ERα protein
(suppressed at 12.5 μM H2O2), relative to parental and
non-targeting control (NTC) expressing cells (50 μM
H2O2). Conversely, PRDX1 overexpression rendered the
cells resistant to suppression of ERα by oxidative stress
Figure 3 Prognostic value of PRDX1 protein in primary ER-positive breast tumors on an independent TMA (cohort 2). Kaplan-Meier
analysis showing associations between (A) RFS, (B) BCSS and (C) OS with high/low PRDX1 expression stratified by the median. The overall and
ER + cohorts are shown. Significant P values are in italic (P <0.05). BCSS, breast cancer-specific survival; ER, estrogen receptor; OS, overall survival;
PRDX1, peroxiredoxin 1; RFS, recurrence-free survival; TMA, tissue microarray.
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stress-induced Akt phosphorylation (Ser473) with phos-
phorylation occurring at a lower H2O2 concentration
(Figure 5B). This effect was also seen when cells were
treated with the reactive nitrogen species, peroxynitrite
(Figure 5C), which was in accordance with previousobservations in other ER-positive breast cancer cell
lines [34]. Although H2O2 induced a decrease of E-
cadherin protein expression in breast cancer cells [35]
(Figure S2A in Additional file 4), these changes were
only minimally affected by changes in PRDX1 expression.
Also, H2O2 induced only marginal or no changes in
Table 2 Cox univariate and multivariate analysis of RFS, BCSS and OS in cohort 2 (TMA), and also stratified into the
ER-positive cohort
RFS BCSS OS
HR (95% CI) P HR (95% CI) P HR (95% CI) P
All patients (n = 432)
PRDX1 protein expression Univariate Univariate Univariate
Low 1 1 1
High# 0.71 (0.50 - 1.02) 0.063 0.81 (0.62 - 1.04) 0.102 0.66 (0.42 - 1.04) 0.071
PRDX1 protein expression Multivariate* Multivariate* Multivariate*
Low 1 1 1
High# 0.78 (0.52 - 1.16) 0.218 0.76 (0.45 - 1.28) 0.302 0.76 (0.56 - 1.03) 0.076
ER + patients (n = 365)
PRDX1 protein expression Univariate Univariate Univariate
Low 1 1 1
High# 0.60 (0.40 - 0.89) 0.012 0.69 (0.52 - 0.92) 0.010 0.44 (0.25 - 0.75) 0.003
PRDX1 protein expression Multivariate* Multivariate* Multivariate*
Low 1 1 1
High# 0.62 (0.40 - 0.96) 0.032 0.44 (0.24 - 0.79) 0.006 0.61 (0.44 - 0.85) 0.004
*Multivariate analysis included adjustment for tumor size, grade, age, nodal, ER, PR, Her2 and Ki67 status. PRDX1 protein expression levels stratified by the median.
#PRDX1 protein expression levels are stratified by the median protein expression value. BCSS, breast cancer-specific survival; CI, confidence interval; ER, estrogen
receptor; Her2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival; PR, progesterone receptor; PRDX1, peroxiredoxin 1; RFS,
recurrence-free survival; RPPA, reverse phase protein arrays.
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regardless of PRDX1 expression levels [36,37] (Figure 5).
This is consistent with the selectivity of the association
between PRDX1 and ER expression. ER activity was also
assessed using an estrogen transcriptional response element
(ERE)-luciferase reporter assay, whereby PRDX1 knock-
down could potentiate oxidative stress-mediated sup-
pression of ERα activity (25 μM H2O2: P = 0.027; 50 μM:
P = 0.037; 100 μM: P = 0.002) (Figure S2B in Additional
file 4). In order to determine if PRDX1 expression was
driven by ERα promoter activity, we assessed PRDX1
protein expression in ZR-75-1 cells with or without
stimulation with the ER ligand, 17β-estradiol. No change in
PRDX1 protein content was seen following 17β-estradiol
stimulation, and as expected, ERα protein is suppressed
upon estradiol stimulation (Figure S2C in Additional file 4).
Although ESR1 mRNA expression is decreased by induc-
tion of oxidative stress (Figure S3A in Additional file 5),
PRDX1 silencing does not enhance this suppression.
Alternatively in PRDX1-silenced ZR-75-1 cells, an ESR1
induction is seen at lower H2O2 concentrations, which
returns to baseline levels above 50 μM H2O2. Importantly,
Supplementary Figure S3B (Additional file 5) demon-
strates that ERα protein levels diminished in these
PRDX1-silenced cells across all H2O2 concentrations
used, which suggests that PRDX1 differentially regulates
ERα mRNA and protein expression. ZR-75-1 cells were
treated with H2O2, and a transcription inhibitor (actino-
mycin D) (Figure S3C in Additional file 5) or proteasomeinhibitor (MG132) in order to determine if oxidative stress
affects ERα protein stability rather than mRNA levels.
These results showed that inhibition of proteasomal deg-
radation using MG132 prevents oxidative stress-induced
ERα suppression and this inhibition is enhanced in the
absence of PRDX1 expression (Figure S3D in Additional
file 5), which suggests that the proteasomal degradation
of ERα via is more active under low-PRDX1 conditions.
This implies that PRDX1 may protect ERα from oxidative
stress-induced suppression of the protein itself, rather than
transcriptional/mRNA stability regulation. In addition,
silencing of PRDX1 in ZR-75-1 and T47D cells did not
alter the cell proliferation and apoptosis (Figure S4A-D
in Additional file 6).
As expected, PRDX1 shRNA-expressing cells showed a
reduced potential to metabolize extracellular H2O2, simi-
lar to the effects of adenanthin, a chemical inhibitor of
PRDX1 and PRDX2 antioxidant activity [20] (Figure S2C
in Additional file 4). Similar to the effect of exogenous
H2O2 treatment, inhibition of PRDX1 antioxidant activity
using adenanthin suppressed ERα levels (Figure 5D; redu-
cing gel). Interestingly, treatment of T47D and ZR-75-1
cell lines with adenanthin resulted in a decrease of PRDX1
dimerization with a dose-dependent increase in PRDX1
monomer levels (Figure 5D; non-reducing gel), which has
not been previously reported. Silencing of PRDX1 or
PRDX2 diminishes the adenanthin-induced suppression
of ERα protein (Figure S5 in Additional file 7). This
suggests that PRDX1 and PRDX2 might both have similar
Figure 4 PRDX1 protein expression and correlation with cancer-signaling proteins in ER-positive tumors from the TCGA RPPA cohort
(cohort 3). (A) ERα protein distribution across all breast tumors as measured by RPPA. The threshold for ER-negative and -positive cases was < -1.9
and > -1.4 of the log2 transformed signal, respectively. (B) PRDX1 protein distribution across the ER-positive cohort (n = 289). (C) Differentially expressed
proteins between the upper and lower quartiles of PRDX1 protein expression (quartile size: n = 72) in ER-positive tumors. ERα and Claudin-7 are upregulated
while Collagen-VI, pT202/pY204-MAPK and HSP70 are downregulated in PRDX1 high tumors. These proteins are selected based on the adjusted P value
<0.05 and FCabs <0.67 or >1.5. ER, estrogen receptor; PRDX1, peroxiredoxin 1; RPPA, reverse phase protein arrays; TCGA, The Cancer Genome Atlas.
O’Leary et al. Breast Cancer Research 2014, 16:R79 Page 10 of 15
http://breast-cancer-research.com/content/16/4/R79and/or partially overlapping effects in protecting ERα
from degradation. Importantly for this study, however,
adenanthin was initially described as a more potent in-
hibitor of PRDX1 than PRDX2, as adenanthin had a sig-






MAPK-pT202-Y204 MAPK1 MAPK3 0.6505
Collagen-VI COL6A1 0.6074
HSP70 HSPA1A 0.6057
*Significant adjusted P value (P <0.05) highlighted in italics. #FC, fold change. ER, esfor PRDX1 (1.5 μM) compared to PRDX2 (15 μM) [20].
Indeed, MCF7 cells, which express levels of PRDX1
comparable to ZR-75-1 and T47D, but significantly
more PRDX2 protein, require higher concentrations of
adenanthin in order to suppress ERα (Figure S5D-E inhort 3 after stratification into the ER-positive cohort







trogen receptor; PRDX1, peroxiredoxin 1.
Figure 5 Effect of PRDX1 knockdown and overexpression on the response of ERα protein expression following induction of oxidative
stress in breast cancer cells. (A) PRDX1 knockdown sensitizes these ER-positive cells to H2O2-mediated ERα protein suppression while
overexpression allows the cells resistance to this suppression. (B) PRDX1 knockdown sensitizes these cells to the concurrent phosphorylation of Akt at
Serine-473 after treatment with increasing concentrations of H2O2, while it does not markedly alter expression of E-cadherin or phosphorylation of
ERK1/2 after treatment with increasing concentrations of H2O2 for 16 hours. (C) PRDX1 knockdown sensitizes the cells to peroxynitrite-induced
suppression of ERα and phosphorylation of Akt. (D) Inhibition of the antioxidant activity of PRDX1 using adenanthin suppresses ERα levels in ZR-75-1
and T47D cells, with gradual PRDX1 monomer formation. All treatments were 16 hours in duration. (Comp: complete medium only; DegPer: degraded
peroxynitrite). ER, estrogen receptor; H2O2, hydrogen peroxide; PRDX1, peroxiredoxin 1.
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is a primary target for adenanthin, and that PRDX2 can
partially substitute for PRDX1-mediated protection of
ERα. This potentially opens a new avenue for further
investigation of PRDX2 in ER-positive breast cancer.
Discussion
In order to improve the outcomes for patients, advances
in understanding of the pathophysiology of breast cancer
combined with the identification of proteins and molecu-
lar pathways that affect key proliferation and survival
mechanisms are needed. The discovery and validation of
these molecular biomarkers requires the integration of
several platforms, and antibody-based proteomics allowshigh-throughput identification and validation of candidate
biomarkers (reviewed in [38]).
The aim of this study was to elucidate the association
between PRDX1 protein levels and survival in two inde-
pendent breast cancer cohorts, using two orthologous
methods of assessing protein expression levels, namely
RPPA and TMA technology. With RPPA, protein lysates
are denatured and immobilized to the slide, a similar
approach to immunoblotting, and it offers a more quan-
titative approach for profiling protein expression levels.
This proteomic technique has become extremely useful
for screening tumor lysates in respect to expression of
candidate protein biomarkers. TMAs allow for the IHC-
based validation of protein biomarkers, where one could
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and, in particular, to assess spatial pattern of expression
which is lost in the RPPA approach. Therefore, both
techniques used in this study complement and support
each other.
After initially screening a large cohort of breast cancer
patients to assess the prognostic potential of PRDX1, we
observed that in the ER-positive subset of tumors, high
PRDX1 protein expression was associated with improved
survival. While RPPA analysis is useful for testing the
prognostic ability of biomarkers on limited amounts of
tissue, we set about validating these findings using IHC
in an independent cohort. Once again, high PRDX1 ex-
pression was associated with improved RFS, OS and BCSS
in ER-positive patients. In this case, PRDX1 was also an
independent predictor of improved survival when adjusted
for other clinicopathological variables.
This is the first report showing a functional connection
between expression of PRDX1 and ERα in breast cancer.
As PRDX1 is a natural antioxidant enzyme, we were inter-
ested in further elucidating the links between PRDX1,
ROS and regulation of ERα levels in breast cancer. ROS
are endogenously produced in all metazoan organisms as
a result of aerobic respiration. ROS are essential regulators
of cell signaling pathways; however, oxidative stress can
occur if ROS production exceeds the capacity of the anti-
oxidant machinery, of which the peroxiredoxin enzymes
constitute important members. It has been suggested that
the role of oxidative stress in ER-positive breast cancer
may be different than in other tumor types [39]. Several
studies have demonstrated in vitro that mitochondrial
ROS can be induced by physiological estrogen concentra-
tions [40,41]. As oxidative metabolism of estrogen and
subsequent formation of ROS are key estrogen-related
carcinogenic mechanisms [42,43], ROS scavenging sys-
tems are expected to play a particularly important role
in ER-positive malignancies.
Utilizing an independent cohort of patients (cohort 3),
we screened for cancer-related signaling proteins altered
in PRDX1 positive tumors. ERα protein is upregulated in
PRDX1-high tumors. Although this correlation is of modest
potency, it supports our mechanistic observations in vitro,
as regulation of ERα expression in cells depends on a
multiplicity of factors, with PRDX1-mediated protection
representing only one. This screening approach also
identified other cancer progression-related proteins
differentially regulated by PRDX1 in the ER-positive
cohort. PRDX1 is positively correlated with the tight
junction protein, Claudin-7 [44], while negatively cor-
related with several proteins involved in malignant cell
transformation and epithelial-mesenchymal transition
(EMT): the pro-EMT molecule, Collagen VI, [45]; heat
shock chaperone protein, HSP-70 [46]; and the phosphory-
lated form of ERK1/2 (pT202/pY204). These results suggestthat PRDX1 may interact with different intracellular ligands
within ER-positive tumors, possibly explaining the asso-
ciation of PRDX1 to improved outcomes amongst the
ER-positive tumor subtypes. Further studies may elucidate
the functional role of the interactions between PRDX1
and these proteins.
Our in vitro studies suggest that PRDX1 may play a
role as a regulator of the balance between ERα-mediated
and oncogene-induced growth patterns in this disease.
Specifically, PRDX1 helps to maintain ERα protein levels
under oxidative stress, and inhibits the activation of Akt
under oxidative stress. This function may be particularly
interesting due to the association between PI3K pathway
hyperactivity and lower ER levels and activity in ER-
positive breast cancer [47]. Although PRDX1 can regulate
PTEN [6], the phosphatase that acts upstream of Akt, this
mechanism is not relevant in ZR-75-1 cells, as these cells
are PTEN-deficient [48]. Our results suggest that PRDX1
protects ERα indirectly through scavenging of H2O2, as
inhibition of antioxidant activity using adenanthin sup-
presses ERα expression. In addition, the oligomeric
state of cellular PRDX1 is a key indicator of PRDX1
function, with dimers primarily acting as an antioxi-
dant scavenger and decameric PRDX1 functioning as a
molecular chaperone [49-51]. However, follow-up experi-
ments using PRDX1 mutants would further tease out this
mechanism. PRDX1 C51/172S mutants are unable to form
dimeric the PRDX1 structures required for antioxidant ac-
tivity [52], while the PRDX1 mutant (C83S) is incapable of
producing decameric PRDX1. Treatment of both PRDX1
mutant cell lines with H2O2 would further allow the
elucidation of the role of PRDX1 in the protection of
ERα. Furthermore, assessment of ERα expression after
adenanthin treatment in the presence and absence of
H2O2 could elucidate this mechanism.
Due to high homology between PRDX1 and PRDX2,
we also assessed the ability of PRDX1 in maintaining
ERα protein levels in absence of PRDX2. This approach
showed that both proteins can independently contribute
in vitro to protecting ERα protein expression. Further
in vivo studies would elucidate the functional overlap
between these two peroxiredoxins in breast cancer.
Recent studies identified an oxidant-sensitive subset of
estrogen/ER-responsive breast cancer genes linked to cell
growth and invasion pathways that was associated with
loss of progesterone receptor and earlier disease-specific
mortality [53]. Assuming that oxidative stress contributes
to the development of an aggressive subset of primary ER-
positive breast cancers, these findings suggest that PRDX1
may be able to protect against these oxidative stress-
induced changes in cellular phenotype. It is important to
notice that associations with PRDX1 and the endocrine
system have been recently described in prostate cancer, in-
cluding effects of PRDX1 on androgen receptor activity
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Along with our report, this suggests a key role for PRDX1
in regulation of the activity of steroid hormone-related
pathways. Interestingly, it has been suggested that re-
sistance to endocrine therapy may be mediated, in part,
by ROS-mediated dysregulation of estrogen signaling
pathways (reviewed in [56]).
Previous studies on PRDX1 expression did not find an
association with clinicopathological features or prognosis
in human breast cancer [12,13]. Potentially, the antibodies
used by these studies may lack specificity for PRDX1 or
alternatively, in contrast to the large sample sets studied
herein, insufficient sample numbers and power may have
precluded detection of associations with outcomes.
Significantly, one of the above mentioned studies reports
a strong nuclear pattern of PRDX1 expression as deter-
mined by IHC staining (Figure 1A in [13]), compared to
our observation where PRDX1 is predominantly cytoplas-
mic. This discrepancy underscores the need for rigorous
testing of antibodies in biomarker studies. Our antibody
validation model includes testing using recombinant cell
lines and tumor tissues across several platforms of protein
quantification (immunoblotting, RPPA, cell pellet arrays,
TMAs). Altogether, this study provides a model to acceler-
ate the validation of potential biomarkers on the transla-
tional journey to the clinic.
Conclusions
In conclusion, we have identified PRDX1 protein as an
independent predictor of favorable prognosis in ER-positive
breast carcinomas. Based on our accumulated data, we
hypothesize that PRDX1 shields the dependence of mam-
mary tumors on estrogen-mediated growth stimulation,
which eventually is of benefit for the patient. In this re-
gard, PRDX1 expression may be utilized in the therapeutic
decision-making process in this disease in the future.
Moreover, our results suggest that any prospective PRDX1
inhibitors should be explored with caution in ER-positive
breast cancer due to the potential to convert tumor cells
to a more aggressive phenotype with a worsened outcome.
Additional files
Additional file 1: Supplementary Methods. Additional methods not
described in the main body of text.
Additional file 2: Table S1. Clinicopathological parameters for the
three cohorts of breast cancer patients utilized in this study. Table S2.
Association of PRDX1 expression with clinicopathological parameters in
the RPPA cohort (cohort 1). Table S3. Association of PRDX1 expression
with clinicopathological parameters in the consecutive cohort (cohort 2).
Table S4. Proteins that correlate with PRDX1 protein expression in the
ER-positive and/or ER-negative cohort. ER, estrogen receptor; PRDX1,
peroxiredoxin 1; RPPA, reverse phase protein arrays.
Additional file 3: Figure S1. Additional antibody validation experiments.
(A) Full length immunoblotting gel shows a single discrete signal, the
intensity of which correlates with PRDX1 knockdown/overexpression acrossrecombinant ZR-75-1 cell lines (V5-tagged PRDX1 protein runs at 25 kDa,
with native protein at 22 kDa). (B) Immunoblotting signal in PRDX1-silenced
ZR-75-1 cell lines using independent PRDX1-targeting antibodies. (C) Protein
and transcript expression were compared across three recombinant ZR-75-1
cells lines (NTC shRNA, PRDX1-sh1, PRDX1-sh2), which shows a greater
correlation using the antibody from Atlas antibodies (solid line) compared
to the Abcam antibody (dotted line). (D) Overexpression of PRDX1 in
ZR-75-1 cells did not affect PRDX2 protein expression, while PRDX2
overexpression in T47D cells did not affect PRDX1 protein expression.
NTC, non-targeting control; PRDX1, peroxiredoxin 1; shRNA, short
hairpin loop RNA.
Additional file 4: Figure S2. Additional in vitro Western blotting and
functional assays. (A) Effect of H2O2 on ERα, pSer473-Akt and E-cadherin
levels, along with respective loading controls. Parental ZR-75-1 cells were
treated with increasing levels of H2O2 for 16 hours. (B) PRDX1 knockdown
enhances the H2O2-mediated suppression of ER activity. Relative units of
the ERE-luciferase reporter expression were normalized to Renilla-luciferase
units. H2O2 treatment was 16 hours in duration. (C) PRDX1 protein expression
is not driven by ER activity. Western blot analysis shows that no change in
PRDX1 protein expression following stimulation of parental ZR-75-1 cells with
1 or 10 nM 17-β estradiol for 48 hours. During this experiment, these cells
were cultured in DMEM containing 0.1% FBS supplemented with 17-β
estradiol or vehicle control. (D) Treatment with adenanthin inhibits
metabolism of H2O2 following three hours treatment with 50 μM H2O2.
Knockdown of PRDX1 (sh2) is shown as a positive control. (ns: non-significant;
*P <0.05; **P <0.01). DMEM, Dulbecco’s modified Eagle’s medium; ER, estrogen
receptor; ERE, estrogen transcriptional response element; FBS, fetal bovine
serum; H2O2, hydrogen peroxide; PRDX1, peroxiredoxin 1.
Additional file 5: Figure S3. Effects on mRNA expression and protein
stability after H2O2 treatment. (A) ESR1 mRNA expression is suppressed
after induction of oxidative stress (16 hours H2O2 treatment) in ZR-75-1
cells. Silencing of PRDX1 does not enhance this oxidative stress-mediated
suppression of ESR1 mRNA. Error bars represent the SEM from independent
biological experiments (*P <0.05; **P <0.01). (B) H2O2 treatment suppresses
ERα protein expression in these PRDX1-silenced ZR-75-1 cells. (C) Inhibition
of transcription (1 μg/μl Actinomycin D) does not alter H2O2-mediated
suppression of ERα protein. (D) Inhibition of proteasomal degradation (5 μM
MG132) prevents oxidative stress-induced ERα suppression in ZR-75-1 cells.
After inhibition of proteasomal degradation, PRDX1-sh2 expressing cells
display a weaker H2O2-mediated suppression. All treatments were 16 hours
in duration. ER, estrogen receptor; H2O2, hydrogen peroxide; PRDX1,
peroxiredoxin 1.
Additional file 6: Figure S4. Viability and apoptosis assays. PRDX1
knockdown does not alter cell growth or viability in ZR-75-1 and T47D
breast cancer cell lines. ZR-75-1 (A) and T47D (B) cells were grown in
normal medium for up to 120 hours, with cell viability (MTT assay) being
measured every 24 hours. Experiments were repeated three times with
six wells per experiment. Error bars represent the SEM. (C) Flow cytometry
viability analysis (7-AAD viability staining solution) was also used to
demonstrate this lack of change in proliferation. (D) The Apotox-Glo™
Triplex assay kit was used to measure caspase 3/7 activity in PRDX1 or
PRDX2-silenced ZR-75-1 cells compared to the parental and NTC
shRNA controls. Error bars represent the SD (ns: non-significant).
PRDX1, peroxiredoxin 1.
Additional file 7: Figure S5. PRDX2 RT-PCR and Western blotting,
including adenanthin treatment of PRDX2-silenced cells. (A) PRDX2
mRNA and (B) protein expression is reduced in ZR-75-1 and T47D cells
after lentiviral transduction of up to five different anti-PRDX2 shRNAs. (C)
Silencing of PRDX1 or PRDX2 abrogates the adenanthin-induced suppression
of ERα protein in ZR-75-1. All treatments were 16 hours in duration. Error bars
represent the SEM from two independent experiments (***P <0.001). ER,
estrogen receptor; PRDX1, peroxiredoxin 1; RT-PCR, real-time polymerase
chain reaction; shRNA, short hairpin loop RNA.
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